Lumanity will be sponsoring, attending, and presenting at the Market Access for CNS Therapeutics Summit where attendees will have the “opportunity to obtain hyper-relevant insights unique to the CNS marketplace to shape evidence programs for commercial success.”
Presentations:
Starting with the End in Mind: Strategic Access Planning at the Earliest Stages for CNS Therapeutics
September 24, 2025 | 10:30 am – 11:00 am
- CNS drugs face uniquely complex access hurdles: diagnostic ambiguity,
subjective endpoints, societal stigma, infrastructure gaps, and payer scepticism
toward psychiatric or neurodegenerative indications - Market access strategy cannot wait until Phase 3 – strategy and decisions need to
be made at the earliest stages of development to lock in value later
Key Questions
- Why is it essential to begin market access planning before clinical proof of
concept, particularly for CNS assets? - How do you define and stress-test a Target Product Profile (TPP) at the pre–
Phase 2 stage to align with future payer and HTA expectations? - What is different about market access planning in CNS vs. other therapeutic
areas at this stage?
Reach out to Ginger Johnson directly to set up a meeting, or email contact@lumanity.com.